Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has announced it will release its third quarter 2024 financial results after market close on November 28, 2024. The company will hold a conference call to discuss the results and business developments on December 3, 2024 at 4:30 p.m. ET. Participants are required to register for the call in advance, with recommended joining time being 10 minutes before the event. A webcast will be available on Kane Biotech's website in the Investor section.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il 28 novembre 2024. L'azienda terrà una conferenza telefonica per discutere i risultati e gli sviluppi aziendali il 3 dicembre 2024 alle 16:30 ET. I partecipanti sono tenuti a registrarsi in anticipo per la chiamata, con un tempo di accesso consigliato di 10 minuti prima dell'evento. Un webcast sarà disponibile sul sito web di Kane Biotech nella sezione Investor.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el 28 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica para discutir los resultados y los desarrollos comerciales el 3 de diciembre de 2024 a las 4:30 p.m. ET. Se requiere que los participantes se registren con anticipación para la llamada, y se recomienda un tiempo de acceso de 10 minutos antes del evento. Una transmisión web estará disponible en el sitio web de Kane Biotech en la sección de Inversores.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF)가 2024년 3분기 재무 결과를 2024년 11월 28일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 2024년 12월 3일 오후 4시 30분 ET에 결과 및 사업 개발에 대해 논의하기 위한 전화 회의를 개최합니다. 참가자는 사전에 전화 회의에 등록해야 하며, 권장 접속 시간은 이벤트 시작 10분 전입니다. Kane Biotech 웹사이트의 투자자 섹션에서 웹캐스트를 이용할 수 있습니다.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 après la clôture du marché le 28 novembre 2024. La société organisera une conférence téléphonique le 3 décembre 2024 à 16h30 ET pour discuter des résultats et des développements commerciaux. Les participants doivent s'inscrire à l'avance pour l'appel, avec un temps de connexion recommandé de 10 minutes avant l'événement. Un webcast sera disponible sur le site Web de Kane Biotech dans la section Investisseur.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) hat angekündigt, dass es seine Finanzergebnisse für das 3. Quartal 2024 nach Marktschluss am 28. November 2024 veröffentlichen wird. Das Unternehmen wird am 3. Dezember 2024 um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse und Geschäftsentwicklungen zu besprechen. Die Teilnehmer müssen sich im Voraus für die Konferenz anmelden, wobei eine empfohlene Einwahlzeit von 10 Minuten vor der Veranstaltung liegt. Ein Webcast wird auf der Website von Kane Biotech im Bereich Investoren verfügbar sein.
- None.
- None.
Conference Call to be held on December 3, 2024
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thursday, November 28, 2024.
Kane Biotech management will host a conference call at 4:30 p.m. ET on December 3, 2024 to review the financial results and discuss business developments in the period.
Participants must register for the call using the following link: Dec 3, 2024 Conference Call. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A webcast of the call will be available on Kane Biotech’s website at www.kanebiotech.com in the Investor section at ir.kanebiotech.com.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
| Marc Edwards | Ray Dupuis | ||||
| Chief Executive Officer | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
When will Kane Biotech (KNBIF) release Q3 2024 earnings?
When is Kane Biotech's (KNBIF) Q3 2024 earnings call?
Where can I access Kane Biotech's (KNBIF) Q3 2024 earnings webcast?
